129644-57-1

Usage

Uses

Used in Pharmaceutical Industry:
2-HYDROXY-5-(TRIFLUOROMETHOXY)BENZOIC ACID is used as a building block for the synthesis of various pharmaceuticals, leveraging its chemical structure to contribute to the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Industry:
In the agrochemical sector, 2-HYDROXY-5-(TRIFLUOROMETHOXY)BENZOIC ACID is utilized in the formulation of insecticides and herbicides, providing a foundation for creating effective pest control agents.
Used in Dye and Pigment Production:
2-HYDROXY-5-(TRIFLUOROMETHOXY)BENZOIC ACID is employed as a key component in the production of dyes and pigments, contributing to the coloration and stability of these products in various applications.
Used in Organic Synthesis:
As a versatile chemical intermediate, 2-HYDROXY-5-(TRIFLUOROMETHOXY)BENZOIC ACID is used in organic synthesis for the creation of a wide range of chemical compounds, expanding its utility across different industries.
Used in Drug Development:
Due to its biological activities, including anti-inflammatory and antioxidant properties, 2-HYDROXY-5-(TRIFLUOROMETHOXY)BENZOIC ACID is used in drug development for the potential treatment of various conditions, highlighting its importance in the pharmaceutical research and development process.

InChI:InChI=1/C8H5F3O4/c9-8(10,11)15-4-1-2-6(12)5(3-4)7(13)14/h1-3,12H,(H,13,14)

Upstream product

• 93249-62-8 2-hydroxy-5-(trifluoromethoxy)benzaldehyde 
• 191604-88-3 2-methoxy-5-(trifluoromethoxy)benzoic acid 
• 851341-40-7 1-(methoxymethoxy)-4-(trifluoromethoxy)benzene 
• 828-27-3 4-Trifluoromethoxyphenol 
• 124-38-9 carbon dioxide 

Downstream Products

• 177174-55-9 (2-Hydroxy-5-trifluoromethoxy-phenyl)-pyridin-2-yl-methanone 
• 175204-89-4 methyl 2-hydroxy-5-(trifluoromethoxy)benzoate 
• 935534-18-2 methyl 3-amino-2-hydroxy-5-(trifluoromethoxy)benzoate 
• 935534-17-1 methyl 2-hydroxy-3-nitro-5-(trifluoromethoxy)benzoate 
• 129644-59-3 2-Hydroxy-5-trifluoromethoxybenzamide 

Relevant academic research and scientific papers

Metabolites of (+)-(2S,3S)-3(2-methoxy-5- trifluoromethoxybenzylamino)-2-phenyl-piperidine

Metabolites of (+)-(2S, 3S)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine, and use of same.

The site-selective functionalization of halogen-bearing phenols: An exercise in diversity-oriented organometallic synthesis

The organometallic approach to diversity-oriented organic synthesis was subjected to a further test, this time in the phenol series. The model compounds selected were 2,3,6-trifluorophenol, the three isomers of (trifluoromethoxy) phenol and the three isomers of chlorophenol. A combination of optionally site selective metalations and protective group-controlled metalations enabled the selective generation of several isomeric intermediates in each case and their subsequent conversion into functionalized derivatives, in particular hydroxybenzoic acids.

Design and synthesis of highly potent and selective (2-arylcarbamoyl- phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications

Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid aldose reductase inhibitors. The compound class features a core template that utilizes an intramolecular hydrogen bond to position the key structural elements of the pharmacophore in a conformation, which promotes a high binding affinity. The lead candidate, example 40, 5-fluoro-2-(4-bromo-2-fluoro-benzylthiocarbamoyl)-phenoxyacetic acid, inhibits aldose reductase with an IC50 of 30 nM, while being 1100 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. In addition, example 40 lowers nerve sorbitol levels with an ED50 of 31 mg/kg/d po in the 4-day STZ-induced diabetic rat model.

Substituted phenoxyacetic acids

Disclosed are substituted phenoxyacetic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds, alone or in combination with other therapeutic agents, and methods of treatment employing the compounds and pharmaceutical compositions, as well as methods for their synthesis.

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers

A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2-induced and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for oral hypotensive effects in spontaneously hypertensive rats. An electron- withdrawing group with the proper shape at C6 and a methyl or halogens group at C7 of the 1,3-benzoxazine nucleus were required for the development of optimal vasorelaxant and hypotensive activity. In particular, 2-(6-bromo-7- chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine 1-oxide (71) showed more potent vasorelaxant activity (EC50=0.14 μM) against TEA and BaCL2- induced contraction and longer-lasting hypotensive effects than cromakalim (1).